BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

Summary

  • On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year.
  • As is the case with all micro-cap biotechs, investors remain skeptical due to the expected cash burn until, surely after, a possible approval.
  • Not only does BioLineRx has sufficient liquidity for the next two years, but there are additional catalysts along the next 18 months.
  • We believe that BLRX has a good chance to be bought out for a stock price in the mid-high teens, possibly before 2022 comes to an end.
  • Looking for a portfolio of ideas like this one? Members of Wheel of Fortune get exclusive access to our model portfolio. Learn More »
New year 2021 road start
alexsl/iStock via Getty Images

May 4, 2021: A New Era Has Begun

May 4, 2021, was a transformational day for BioLineRx (NASDAQ:BLRX).

On that day, the company announced positive results from Phase 3 GENESIS trial - the company's most-advanced clinical study, evaluating Motixafortide (aka BL-8040), in combination with

Mid-year Review = Mid-year Sale

Join Wheel of Fortune ("WoF") or Macro Trading Factory ("MTF") before the end of June under our special offer, and gain access to our regular features, but also to our mid-year review, covering:

  • our general-macro views
  • updated ratings and allocations to all 11 S&P500/GiCS sectors
  • specific touch to each and every position held in (or to be added to) our Funds Macro Portfolio.

WoF: $959 (-26.2%) for the 1st year, $1,199 (-7.7%) then after

MTF: $499 (-12.0%) for the 1st year, $567 then after 

This article was written by

21.71K Followers

The Fortune Teller is a team of two analysts with over 30 years of market experience between them. One of the principles is a formerly licensed investment advisor with a background in asset management. They also hold BAs in Accounting & Economics and Computer Sciences, as well as MBAs, which they use to inform their stock selections

They lead the investing group Wheel of Fortune where they share actionable trading ideas across all asset-classes, sectors and industries. The goal of the service is to provide a one-stop-shop for investment and portfolio ideas, while educating the vibrant community of subscribers. Features of the service include: the Funds Macro Portfolio (only ETFs and CEFs) for less active investors, the Single Macro Portfolio (single equity focused) for more active investors, educational content, and a live chat room to openly discuss ideas with like-minded investors and The Fortune Teller. Learn more.

Analyst’s Disclosure:I am/we are long BLRX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About BLRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BLRX

Related Stocks

SymbolLast Price% Chg
BLRX
--